Home | Hepatitis C News
HEPATITIS C NEWS
- FDA Approves Rapid Test for Antibodies to Hepatitis C Virus
READ NEWS - Vitamin A and Treatment
READ NEWS - Efforts to Up Minority Organ Donations Show Success
READ NEWS - Study Finds Beta Blockers Alone More Effective for First Variceal Bleeding
READ NEWS - Antiviral Therapy during Compensated Cirrhosis Most Cost-Effective Approach Treatment
READ NEWS - Study Finds Poor Compliance with Cirrhosis Surveillance Recommendations Less than 20% of Qualified Patients Are Regularly Monitored
READ NEWS - Peginterferon alfa-2B and Ribavirin for Liver Transplant Patients Yields 30% HCV SVR
READ NEWS - Modest" Results With Nitazoxanide for HCV Genotype 1 Nonresponders
READ NEWS - Study Links Liver Transplantation to Accelerated Cellular Aging
READ NEWS - FDA Considers Expanded Use of HCV Drugs
READ NEWS - Liver Donations from Living Donors Increase 42% after Educational Intervention
READ NEWS - Infectious Disease Screening
READ NEWS - Telaprevir Raises Response Rates in Hepatitis C
READ NEWS - HCV Polymerase Inhibitor VX-222 Demonstrates Good Safety and Antiviral Activity in Treatment-naive Genotype 1 Hepatitis C Patients
READ NEWS - HCV Protease Inhibitor Danoprevir (RG7227/ITMN-191) Shows Antiviral Activity at Lower Doses When Boosted with Ritonavir
READ NEWS - HCV Protease Inhibitor Boceprevir Demonstrates Durable Sustained Response with No Late Relapse
READ NEWS - Vertex Will Study All-Oral Regimen of HCV Protease Inhibitor Telaprevir plus Polymerase Inhibitor VX-222
READ NEWS - U.S. Doctors Sanction Transplant Criteria for Liver Cancer Patients
READ NEWS - Vertex Broadens its Commitment to Improving HCV Care with Clinical Trial to Evaluate Combination Regimens Based on Oral Antiviral Therapies
READ NEWS - Is One Type of Pegylated Interferon More Effective for Treating Chronic Hepatitis C?
READ NEWS - Hepatitis and Liver Cancer: A National Strategy for
Prevention and Control of Hepatitis B and C
READ NEWS - Liver Donations from Living Donors Increase 42% after Educational Intervention
READ NEWS - Vaccines May Lower Viral Load Improve Treatment Response
READ NEWS - African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C
READ NEWS - Metabolic Factors That Predict Rapid Virologic Response to Peginterferon/Ribavirin in HCV Patients
READ NEWS - Weight Loss: A Modifiable Lifestyle Parameter That Can Alter HCV Liver Disease Progression
READ NEWS - Silent Epidemic of Viral Hepatitis May Lead to Boom in Serious Liver Disease
READ NEWS - Direct Antivirals Can Beat HCV Without Interferon
READ NEWS - HCV Response Linked Strongly to Gene Variant
READ NEWS - Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), An Investigational, Once-Daily Protease Inhibitor For Hepatitis C
READ NEWS - More Than 80 Percent Of HCV Genotype 1 Treatment-Naive Patients Achieved Sustained Virologic Response With Twice-Daily Telaprevir-Based Regimen
READ NEWS - Sprint 1 Study, Phase 2, Boceprevir
READ NEWS - Pegylated Interferon Lambda Demonstrates Good Antiviral Activity, May Cause Fewer Side Effects than Interferon Alfa
READ NEWS - Coffee Could Stall Liver Disease Progression
READ NEWS - Hepatitis C Drug Development at a Crossroads - Comments from the Editors
READ NEWS - Hypertension and Diabetes Are Concern in Long-Term Care of Liver Transplant Patients
READ NEWS - The FDA has just issued new warnings in the package inserts for alpha interferons
READ NEWS - Women, Blacks, Medicare Recipients Less Likely To Be Evaluated For Liver Transplantation
READ NEWS - New Biomarker Predicts Response to Hepatitis C Treatment
READ NEWS - Protein & Cholesterol May Increase Risk Of Cirrhosis & Hepatocellular Carcinoima
READ NEWS - Weight-Related Factors Tied to Outcomes of Chronic Hepatitis C
READ NEWS - Head-to-Head Trial Finds HCV Regimens Equal
READ NEWS - Interferon and Ribavirin Second-Line Option for Hepatitis C
READ NEWS - DDW: Interferon Has Long-Term Histo Benefits in HCV
READ NEWS - FDA May Restrict Acetaminophen
READ NEWS - Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1
READ NEWS - DDW: Telaprevir Improves HCV Clearance in Resistant Patients
READ NEWS - Hypothyroidism In Women Associated With Liver Cancer
READ NEWS - Sustained Response Seen with New Hepatitis C Drug
READ NEWS - Re-treatment of Chronic Hepatitis C Patients Who Do Not Respond to Pegylated Interferon Alfa-2b (PegIntron)
READ NEWS - Promising Promising Early Results from the First Clinical Trial of a Combination Regimen of 2 Oral Antiviral Agents for Chronic Hepatitis C
READ NEWS - Necessities of Interferon Therapy in Elderly Patients with Chronic Hepatitis C
READ NEWS - HCV Vaccine Development
READ NEWS - Pegylated Interferon alfa-2a (Pegasys) Relapse Rates in Genotype 1 Chronic Hepatitis C Patients Depend on Weight-based Ribavirin Dosage
READ NEWS - Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C
READ NEWS - Response To Therapy In Chronic Hepatitis C Predicted By 2-Day Results
READ NEWS - Vertex Acquires VCH-222 and VCH-759, Two Experimental Oral HCV Polymerase Inhibitors
READ NEWS - Hepatitis C Linked to Increased Risk of Intrahepatic Cholangiocarcinoma
READ NEWS - Liver Biopsies Indicate Persistent Inflammation and Fibrosis in HCV Antibody Positive People with Undetectable HCV RNA
READ NEWS - Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study with R7128 in Treatment Naive HCV Patients
READ NEWS - Human Genome Sciences Announces Initiation of Phase 2b Trial 0f Albuferon Dosed Monthly in Chronic Hepatitis C
READ NEWS - Although Hepatitis C Treatment Reduces The Virus, Liver Damage Continues
READ NEWS - Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint In Phase 3 Trial In Chronic Hepatitis C
READ NEWS - Pegylated interferon alpha2a is more effective in some hepatitis C patients with specific genotypes than the alpha2b form of the drug, an Italian researcher said
READ NEWS - HCV Polymerase Inhibitor R7128 Demonstrates Good Antiviral Activity in Genotype 2 or 3 Prior Non-responders and Relapsers
READ NEWS - Hepatitis C patients may have abnormal blood sugar
READ NEWS - FDA Approves Nexavar for Patients with Inoperable Liver Cancer
READ NEWS - Sustained Virological Response to Pegylated Interferon Alfa-2b (PegIntron) with or without Ribavirin Predicts Continued Response through 5 Years
READ NEWS - Symptoms and Response to Interferon plus Ribavirin in Children with Chronic Hepatitis C
READ NEWS - Safety and Activity of Once-Monthly Albinterferon Alfa-2b (Albuferon) in Genotype 2/3 Chronic Hepatitis C Patients
READ NEWS - Insulin Resistance Independently Associated With Chronic Hepatitis C
READ NEWS - Pathology of Chronic Hepatitis C in Children: Peds-C Trial
READ NEWS - Silymarin (Milk Thistle) Does Not Affect Hepatitis C Virus Activity or ALT Levels in HCV Patients, but Users Report Fewer Symptoms and Better Quality of Life than Non Users
READ NEWS - Acute Hepatitis C Infection and Spontaneous Viral Clearance in Adults and Children
READ NEWS - How Effective Is Pegylated Interferon plus Ribavirin for HCV Genotype 1 Patients Over Age 50?
READ NEWS - Depression Due to Treatment with Pegylated Interferon plus Ribavirin May Be Under-diagnosed by Clinicians
READ NEWS - HALT-C Trial Shows Minimal Long-term Benefit of Pegylated Interferon Alfa-2a (Pegasys) Maintenance Therapy in Patients with Chronic Hepatitis C
READ NEWS - Use of Epoetin (EPO) to Manage Anemia in Chronic Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin
READ NEWS - Incidence and Predictors of Hepatocellular Carcinoma in Patients With Cirrhosis
READ NEWS - HCV Care by Liver Specialists or Community-Based Practices: Pro & Con
READ NEWS - Decreased HCV-specific Immunity in African-Americans May Help Explain Poorer Response to Antiviral Therapy
READ NEWS - 400,000 IU/mL Is the Optimal Baseline Viral Load Cut-off to Predict Response In Treatment-naive Patients with Genotype 1 HCV
READ NEWS - Liver Stiffness Predicts Portal Hypertension in HCV Cirrhosis
READ NEWS - EASL: Sustained Virologic Response Equals Cure for HCV Infection
READ NEWS - Racial Differences Seen In Steatosis In Patients With Hepatitis C
READ NEWS - New Vaccine Schedule Offers Protection Against Hepatitis A And Hepatitis B
READ NEWS - Interferon Gamma Does Not Reverse Fibrosis in Hepatitis C Patients with Advanced Liver Disease
READ NEWS - Hepatitis C in African Americans
READ NEWS - Three Studies Examine Syringe Exchange Policies in the U.S.
READ NEWS - Short-course Pegylated Interferon for Acute Hepatitis C
READ NEWS - Heavy-Drinking Women with HCV Infection Cut Decade Off Life
READ NEWS - Treatment Response in Cirrhotic Hepatitis C Patients with Portal Hypertension
READ NEWS - Integrating Medical and Mental Health Care Improves Likelihood of Initiation and Adherence to Hepatitis C Treatment
READ NEWS - Rapid Decline of HCV RNA in Patients Treated with VX-950
READ NEWS - Predicting Survival After Liver Transplant
READ NEWS - Patients Who Recover from Hepatitis C Have Lower Risk of Reinfection
READ NEWS - New Therapy Significantly Increases Platelet Count
READ NEWS - Is Hepatitis A and B Screening and Vaccination in Chronic Hepatitis C Patients Effective?
READ NEWS - Sustained Virological Response to PegIntron Plus Ribavirin in Asian and Hispanic Patients
READ NEWS
